BOD1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt BOD1 expression in the A-549 human lung adenocarcinoma cell line. This polyclonal pool provides a loss-of-function model for investigating BOD1-dependent mechanisms without clonal isolation, maintaining a heterogeneous genetic background representative of tumor cell variability. The CRISPR/Cas9-mediated gene disruption targets BOD1, a kinetochore-associated protein essential for accurate chromosome segregation, enabling study of BOD1 loss on mitotic progression and chromosomal stability.
The A-549 cell line was established from the lung tumor tissue of a 58-year-old Caucasian male with lung adenocarcinoma. These epithelial cells are widely employed in cancer biology, respiratory research, and toxicology studies. A-549 cells harbor a KRAS mutation and exhibit characteristics typical of alveolar type II pneumocytes, making them particularly suitable for investigating lung adenocarcinoma-associated signaling pathways and mitotic abnormalities. The cell line’s robust growth and well-characterized karyotype provide a reliable platform for functional genomics studies, including CRISPR-mediated knockouts.
BOD1 is a critical regulator of chromosome biorientation, promoting correction of erroneous kinetochore?Cmicrotubule attachments during mitosis. It recruits protein phosphatase 2A (PP2A) to kinetochores, where PP2A counteracts Aurora B kinase-mediated phosphorylation, stabilizing correct attachments and facilitating mitotic progression. BOD1 interacts with spindle assembly checkpoint components BUB1, BUBR1, and MAD2, and is regulated by CDK1, PLK1, and Aurora B kinase, integrating with MPS1, CDC20, and the APC/C complex to link error correction to checkpoint signaling and cell cycle control.
In A-549 cells, BOD1 disruption compromises chromosome segregation fidelity, leading to increased chromosomal instability??a hallmark of lung adenocarcinoma. This model enables examination of BOD1 loss on mitotic timing, kinetochore?Cmicrotubule attachment dynamics, and spindle assembly checkpoint function in a lung cancer background. Elucidating these processes helps understand the molecular basis of chromosomal instability and its contribution to tumor progression and drug resistance, establishing this polyclonal knockout population as a physiologically relevant system for assessing BOD1 deficiency in cancer.
Typical applications include functional studies of the mitotic checkpoint, cell cycle analysis by flow cytometry, and immunofluorescence microscopy for chromosome alignment. Live-cell imaging tracks mitotic timing and kinetochore dynamics, while co-immunoprecipitation probes BOD1-PP2A interactions. This model is valuable for validating anti-mitotic therapies, such as Aurora B or PLK1 inhibitors. For further information, please contact Ascent Research.
